Match!
Huaxiao Yang
Stanford University
30Publications
9H-index
209Citations
Publications 30
Newest
#1Huaxiao YangH-Index: 9
#2Xulei QinH-Index: 11
Last.Jing Ge
view all 15 authors...
A major challenge in myocardial infarction (MI)-related heart failure treatment using microRNA is the efficient and sustainable delivery of miRNAs into myocardium to achieve functional improvement through stimulation of intrinsic myocardial restoration. In this study, we established an in vivo delivery system using polymeric nanoparticles to carry miRNA (miNPs) for localized delivery within a shear-thinning injectable hydrogel. The miNPs triggered proliferation of human embryonic stem cell-deriv...
#1Timon Seeger (Stanford University)H-Index: 10
#2Rajani Shrestha (Stanford University)H-Index: 3
Last.Matthew Greenhaw (Stanford University)H-Index: 1
view all 19 authors...
Background: Hypertrophic cardiomyopathy (HCM) is frequently caused by mutations in myosin-binding protein C3 (MYBPC3) resulting in a premature termination codon (PTC). The underlying mechanisms of ...
#1Alexa Wnorowski (Cardiovascular Institute of the South)H-Index: 1
#2Huaxiao Yang (Cardiovascular Institute of the South)H-Index: 9
Last.Joseph C. Wu (Cardiovascular Institute of the South)H-Index: 87
view all 3 authors...
Abstract In recent years, drug development costs have soared, primarily due to the failure of preclinical animal and cell culture models, which do not directly translate to human physiology. Organ-on-a-chip (OOC) is a burgeoning technology with the potential to revolutionize disease modeling, drug discovery, and toxicology research by strengthening the relevance of culture-based models while reducing costly animal studies. Although OOC models can incorporate a variety of tissue sources, the most...
#1Xin Zhao (Cardiovascular Institute of the South)H-Index: 3
#2Haodong Chen (Cardiovascular Institute of the South)H-Index: 11
Last.Youngkyun Kim (Cardiovascular Institute of the South)H-Index: 9
view all 20 authors...
Summary Non-human primates (NHPs) can serve as a human-like model to study cell therapy using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). However, whether the efficacy of NHP and human iPSC-CMs is mechanistically similar remains unknown. To examine this, RNU rats received intramyocardial injection of 1 × 10 7 NHP or human iPSC-CMs or the same number of respective fibroblasts or PBS control (n = 9–14/group) at 4 days after 60-min coronary artery occlusion-reperfusion. Cardiac...
#1Oscar J. AbilezH-Index: 24
#2Evangeline Tzatzalos (Stanford University)H-Index: 4
Last.Praveen Shukla (Stanford University)H-Index: 13
view all 21 authors...
Background: The ability to differentiate human pluripotent stem cells (hPSCs) into cardiomyocytes (CMs) makes them an attractive source for repairing injured myocardium, disease modeling, and drug testing. Although current differentiation protocols yield hPSC-CMs to >90% efficiency, hPSC-CMs exhibit immature characteristics. With the goal of overcoming this limitation, we tested the effects of varying passive stretch on engineered heart muscle (EHM) structural and functional maturation, guided b...
#1Xulei Qin (Cardiovascular Institute of the South)H-Index: 11
#2Haodong Chen (Cardiovascular Institute of the South)H-Index: 11
Last.Heike E. Daldrup-Link (Stanford University)H-Index: 40
view all 13 authors...
Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) have become promising tools to repair injured hearts. To achieve optimal outcomes, advanced molecular imaging methods are essential to accurately track these transplanted cells in the heart. In this study, it is demonstrated for the first time that a class of photoacoustic nanoparticles (PANPs) incorporating semiconducting polymers (SPs) as contrast agents can be used in the photoacoustic imaging (PAI) of transplanted hESC-CMs in living...
#1Ming Tao Zhao (Stanford University)H-Index: 2
#2Haodong Chen (Stanford University)H-Index: 11
Last.Youngkyun Kim (Stanford University)H-Index: 9
view all 18 authors...
Abstract Patient-specific pluripotent stem cells (PSCs) can be generated via nuclear reprogramming by transcription factors (i.e., induced pluripotent stem cells, iPSCs) or by somatic cell nuclear transfer (SCNT). However, abnormalities and preclinical application of differentiated cells generated by different reprogramming mechanisms have yet to be evaluated. Here we investigated the molecular and functional features, and drug response of cardiomyocytes (PSC-CMs) and endothelial cells (PSC-ECs)...
1234